MK-2206 2HCl

Catalog No.S1078

MK-2206 2HCl Chemical Structure

Molecular Weight(MW): 480.39

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 570 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 182 Publications

21 Customer Reviews

  • Inhibition of AKT signaling abolishes MKK4 phosphorylation on Ser78 in injured axons. Cultures of sensory neurons were treated with 5 µM MK-2206 or 5 µM GDC-0068 for 1 hr prior to axotomy. Axonal proteins harvested at indicated time points after axotomy were subjected to immunoblot analysis.

    Cell, 2015, 160(1-2): 161-76 . MK-2206 2HCl purchased from Selleck.

    j,k, Gene expression ofMYOCD (j) and ACTA2 ( SMA, k) after applying inhibitors of key components involved in the DDR2 downstream signalling pathway to HSCs cultured within 3D collagen matrix subjected to stretching (ST) (n=3, one-way ANOVA, **P=0.0036, ****P<0.0001). l,m, Expression of SMA was significantly reduced after treatment with related inhibitors in early-stage FμNs. (n=4, one-way ANOVA, ***P=0.001, ****P<0.0001). AKT-i: MK-2206

    Nature Materials, 2017, 16:1252-1261.. MK-2206 2HCl purchased from Selleck.

  • Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck.

    The PI3K or AKT inhibition does not restore sensitivity to WZ4002 in PC9 WZR. PC9GR4 or WZR10 cells were treated with WZ4002 alone at the indicated concentrations or in combination with the AKT inhibitor MK-2206 (1 uM). MK-2206 effectively inhibited AKT in both cells.

    Cancer Discov 2012 2, 934-47. MK-2206 2HCl purchased from Selleck.

  • Rap1b negatively regulates neutrophil transcellular migration by limiting PI3K-Akt signaling. (A-D) Effect of Akt inhibitor MK2206 (2 uM), Src inhibitor PP2 (10 uM), or vehicle control (DMSO) on WT or Rap1b-/- neutrophil functions. (A) Percentage of neutrophil transendothelial migration in 3D migration model. (B) ECM degradation assessed on Oregon green-labeled gelatin matrix; (left) representative images on (bar, 10 um) and (right) bar graph is percentage of matrix degradation. (C) Percentage of cells forming multiple protrusions. (D) Percentage of neutrophils present at junction of activated bEND.3 in 3D migration assay. Mean ?SD; n = 3 independent experiments. **, P < 0.01; ***, P < 0.001; NS, not significant using unpaired Student's t test).

    J Exp Med 2014 211(9), 1741-58. MK-2206 2HCl purchased from Selleck.

    VE-cadherin-induced Akt activation mediates YAP phosphorylation and translocation in ECs. HUVECs were starved for 1h and treated with thrombin (1U) for 1h. Total cell lysates were probed with anti-pAkt, Akt or b-actin antibody. The representative blots of three independent experiments are depicted, and the normalized values for p-Akt are shown. HUVECs were cultured and starved as described as in d and incubated for 8h in complete medium with the Akt inhibitor, MK-2206 (1 uM). pAkt, Akt, pYAP and YAP were detected by western blotting using specific antibodies.

    Nat Commun 2015 6:6943. MK-2206 2HCl purchased from Selleck.

  • Inhibitors of AKT or ERK overcome SDF-1a-mediated resistance to ibrutinib-triggered PARP and caspase 3 cleavage in CXCR4S338X-expressing BCWM.1 cells. CXCR4S338X-expressing WM cells were treated with ibrutinib (0.5 uM) alone or in the presence of SDF-1a (20 nM) and/or the AKT inhibitors MK-2206 (0.5 uM) and AZD-5363 (0.5 uM); or the MEK inhibitors AS-703026 (0.25 uM), AZD-6244 (0.5 uM) and UO126 (5.0 uM). (a) Immunoblotting results for phosphoAKT (S473) and phospho-ERK (T202/Y204) in CXCR4S338X-expressing BCWM.1 cells pretreated with ibrutinib with and without AKT or ERK inhibitors, then subjected to SDF-1a stimulation for 2 min. The inhibitory effect of AZD-5363 on AKT, which is known to paradoxically hyper-phosphorylate pAKT(S473) was confirmed by inhibition of the phospho-activity for the downstream AKT targets glycogen synthase kinase 3b and pS6. (b) Immunoblotting results for cleaved PARP and cleaved caspase 3 in CXCR4S338X-expressing BCWM.1 cells treated with ibrutinib and/or AKT or ERK inhibitors for 6 h at IC50 doses. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

    Leukemia 2015 29(1), 169-76. MK-2206 2HCl purchased from Selleck.

    Induction of apoptosis positively correlates with FOXO3a protein levels and phosphorylation. (a) Treatment of 11 cell lines seeded in 6-well plates with 8 μM MK-2206 or DMSO for 48 hours. Nuclei were harvested for PI staining and FACS analysis and the differences between drug and no drug are displayed as in Figure b. Both conditions were performed in triplo for each cell line. Below the FACS data is a we stern blot of cell lysates from this panel treated with 8 μM MK-2206 or DMSO and harvested at 24 hours. Each cell line name corresponds to the two western lanes below it and the four cell cycle bars above it.

    Cancer Res 2013 73, 2189-98. MK-2206 2HCl purchased from Selleck.

  • IC50 values for an Akt inhibitor (MK-2206) and a MEK inhibitor (U0126) in a panel of mouse and human anaplastic (ATC) and follicular (FTC) carcinoma cell lines. On the bottom, a Western blotting showing the effect on the activation of Akt and ERK1/2 of one hour exposure to these inhibitors (MK-2206: 500 nM, U0126: 10 μM).

    Oncotarget 2011 2, 1109-26. MK-2206 2HCl purchased from Selleck.

    Mean IL-8 concentrations determined by ELISA of the supernatants of HeLa cells infected with wild-type Salmonella. Kinase inhibitors are indicated on the x axis, and the target families of the inhibitors are indicated above each column. CEC, chelerythrine; Pim Inh, Pim-1 inhibitor 2. Inhibitors that significantly affected IL-8 production relative to the control (P < 0.05, Bonferroni post hoc test from one-way ANOVA) are indicated with an asterisk. Relative cell viability is also shown, as determined by reduction of XTT by viable cells. A450, absorbance at 450 nm.

    Sci Signal 2011 4, rs9. MK-2206 2HCl purchased from Selleck.

  • Reducing cellular levels of PtdIns5P by overexpression of PIP4Kα inhibits clonogenic growth of U2OS but enhances cell survival in response to H2O2 stimulation. A) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), PI-103 (0.5 μM), U0126 (5 μM), or SB203580 (5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown. B) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), MK-2206 (1 μM), triciribine (1 μM), KU0063794 (1 μM), or PI-103 (0.5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown.

    FASEB J 2013 27, 1644-56. MK-2206 2HCl purchased from Selleck.

    A. Western blot analysis of pAKT activation in ovarian cancer cell lines treated with exogenous IGF-1. B. Activation of pAKT by IGF-1 in low-grade ovarian cancer cell lines was blocked by the AKT inhibitor MK-2206 in a dose-dependent manner.

    Gynecol Oncol 2011 123, 13-8. MK-2206 2HCl purchased from Selleck.

  • Confocal microscopy images of NO formation. DAF 2 DA-loaded washed platelets (1.0109 platelets/mL) were preincubated at 378C with saline (A), and then stimulated for 1min with 0.1 (B), 1.0 (C) or 10 (D) μM AEA. In Panel (E-F-G) washed platelets were preincubated with 1 μM SR1 (E), 1 Mm MK2206 (F) or 20 μM LY294002 (G), and then stimulated for 1min with 1.0 μM AEA. In panel (H) is reported the effect of 5 mg/mL collagen, used as a positive control. All the experiments were carried out in the presence of 100 μM L-arginine. NO formation was visualized by confocal microscropy as detailed in Methods.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    The AEA effect on eNOS phosphorylation. Washed platelets (1.0109 platelets/mL), preincubated at 378C with saline, 1 μM SR1, 1 μM SR2, 20 μM LY294002, 1 μM MK2206, 1.0 μM EGTA, or 30 μM BAPTA/AM, were stimulated for 1 min with 1.0 μM AEA. At the end of incubation suitable aliquots were immunoblotted with anti-p-eNOSser1177 as detailed in Methods.Blots are representative of five independent experiments.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • Effect of selected agents on NOx and cGMP formation induced by AEA. Washed platelets (1.0109 platelets/mL), prewarmed at 378C with saline or 1mM SR1, 1 μM SR2, 20 μM URB597 (URB), 1 μM MK2206 (MK) or 20 μM LY294002 (LY), were incubated for 1min with 100 μM L-arginine in the presence of 1.0 μM AEA. NOx (panel A) and cGMP (panel B) content were determined as detailed in Methods. Each bar represents the meanSD of five independent experiments carried out in triplicate. Student,s t-test: P <0.0001 versus none;P <0.0005; P <0.005 versus AEA

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    (B) Dose-response curves for DIPG 4 and SF7761 cells treated with the small molecule AKT inhibitor MK-2206 (error bars represent SEM).

    Oncol Rep, 2018, 39(2):455-464. MK-2206 2HCl purchased from Selleck.

  • C.U87MG cells were treated with vehicle or 1 μM MK-2206 for 1 hr, and then irradiated with 6 Gy. Total cell lysate was harvested 1 hr after IR and subjected to Western blot analysis with the indicated antibody. Cells without IR treatment were used as a control.

    D. Cells were treated with vehicle (control) or 1 μM MK-2206 for 1 hr, then irradiated with indicated dosage. 4 hr after IR, cells were fed with drug-free medium, and incubated for another 20 hr at 37°C, after which they were trypsinized and seeded for clonogenic survival assay. Colony-forming efficiency was determined 14 d later.
     

     

    Radiat Oncol 2009 4, 43. MK-2206 2HCl purchased from Selleck.

    MK-2206 2HCL inhibited the sorafenib-induced PI3K/mTOR pathway activation and enhanced the cytotoxic effects of sorafenib in resistant cell lines. (A) HUH-7 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved PARP were revealed by Western blotting. (B) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved RARP were revealed by Western blotting. (C) HUH-7 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (D) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. MK-2206 2HCl purchased from Selleck.

  • Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823, 987-96. MK-2206 2HCl purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of MK-2206 for 3h,followed by 15-minute stimolation of 100ng/ml EGF.

     
     

     

    Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck.

  •  

    PI3K pathway signaling in GDC-0941 and MK-2206 treated MCF-7 derivatives with PIK3CA or  AKT1 mutations. Cells were grown in medium containing 5% FBS and treated with vehicle or increasing concentrations of GDC-0941 (0 nM, 50 nM, 100 nM, and 400 nM) or MK-2206 (0 nM, 100 nM, 250 nM, 1000 nM). After 24 hours of drug treatment, lysates were prepared and equal amounts of protein were load ed onto SDS-PAGE gels and blotted with the indicated antibodies.

    MK-2206 2HCl purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.
Features The first allosteric small molecule inhibitor of Akt to enter clinical development.
Targets
Akt1 [1]
(Cell-free assay)		 Akt2 [1]
(Cell-free assay)		 Akt3 [1]
(Cell-free assay)
8 nM 12 nM 65 nM
In vitro

MK-2206 is an allosteric inhibitor and is activated by the pleckstrin homology domain. MK-2206 inhibits auto-phosphorylation of both Akt T308 and S473. MK-2206 also prevents Akt-mediated phosphorylation of downstream signaling molecules, including TSC2, PRAS40 and ribosomal S6 proteins. [1] MK-2206 inhibits Ras wild-type (WT) cell lines (A431, HCC827, and NCI-H292) more potently when compared to Ras-mutant cell lines (NCI-H358, NCI-H23, NCI-H1299, and Calu-6). MK-2206 also shows synergistic responses in combination with cytotoxic agents such as erlotinib or lapatinib in lung NCI-H460 or ovarian A2780 tumor cells. [2] MK-2206 or siRNA-mediated Akt inhibition strongly activates autophagy in human glioma cells. However, eukaryotic elongation factor-2 (eEF-2) silencing suppresses MK-2206-induced-autophagy, with a promotion of apoptotic cell death. [3]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H292 MmLyR5l1d3SxeHnjJGF{e2G7 M3rBXlMh|ryP NIPGcJU4OiCq MUnEUXNQ MVfJcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? NWrkem1ROjB3N{GwOlk>
A431 NEjqOWtMcW6jc3WgRZN{[Xl? MWm1JO69VQ>? NXnSfml7PSCq NGHEeIJFVVOR MW\TeZBxemW|c3XzJJRp\SC|aXfuZYxqdmdib3[gRYt1KGGwZDDFdos> NWC1bFFTOjB3N{GwOlk>
HepG2 M1PJeWN6fG:2b4jpZ{BCe3OjeR?= M1;YflExKM7:TR?= M4ThXVI1KGh? NILzWlRFVVOR NEjWc3NU\W6|aYTpfoV{KHKnc3nzeIFvfCClZXzsd{B1dyC2aHWgZ5l1d3SxeHnjJIVn\mWldDDv[kB{d3KjZnXubYI> NGHqOXkzOTJyNUmyOS=>
Sk-Hep1 Ml2xR5l1d3SxeHnjJGF{e2G7 NWH1RXNmOTBizszN MYWyOEBp NXHtZmJxTE2VTx?= NHfUeHhU\W6|aYTpfoV{KHKnc3nzeIFvfCClZXzsd{B1dyC2aHWgZ5l1d3SxeHnjJIVn\mWldDDv[kB{d3KjZnXubYI> NWS5NW5COjF{MEW5NlU>
OCUT1 cells harbored PIK3CA (H1047R+/+) MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDSSZhjOyEQvF2= MmHpOUBl M4r1SGROW09? NHr6R5hKSzVyPUCuNVQh|ryP MUWyNVI5QTJ4Nx?=
K1 cells harbored PIK3CA (E542K+/+) M1PybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX6zJO69VQ>? NXHUemVDPSCm NV7sWWJ3TE2VTx?= MlTtTWM2OD1yLkWyJO69VQ>? M1XZd|IyOjh7Mk[3
FTC133 cells harbored PTEN (allele deletion and R130+) MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Hke|Mh|ryP NHjwTlk2KGR? NHPTR5pFVVOR M2f6WmlEPTB;MD6xPEDPxE1? NIPHSmwzOTJ6OUK2Oy=>
C643 cells harbored HRAS (G13R+/−) M1LiZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnzN{DPxE1? MorwOUBl NXHzb5JXTE2VTx?= NF7PeZFKSzVyPUCuNlch|ryP MXeyNVI5QTJ4Nx?=
Hth7 cells harbored NRAS (Q61R+/−) MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYftbWc6OyEQvF2= NVrQO|IyPSCm M2\0fWROW09? NH71Z3dKSzVyPUSuOUDPxE1? NV61SZg{OjF{OEmyOlc>
TPC1 cells harbored RET/PTC1 rearrangement Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnRN{DPxE1? MYe1JIQ> Mn6zSG1UVw>? MWrJR|UxRTBwNUmg{txO NYLId3ZVOjF{OEmyOlc>
Hth74 M{flXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\Ed5c{KM7:TR?= M3K0SFUh\A>? NUX2[o5kTE2VTx?= Mnu5TWM2OD1{LkG5JO69VQ>? NXy2cJhqOjF{OEmyOlc>
KAT18 NW\sR49IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmr6N{DPxE1? M2\FZVUh\A>? M{SxemROW09? MoL1TWM2OD12Lk[yJO69VQ>? M3q2flIyOjh7Mk[3
SW1736 NWjBUVA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYOxNFAh|ryP M1np[VUh\A>? MkC2SG1UVw>? MVfJR|UxRTR5LkW2JO69VQ>? NFTYZngzOTJ6OUK2Oy=>
WRO MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXrUFkyODByIN88US=> M{D4UFUh\A>? Mn;DSG1UVw>? NUXiSppXUUN3ME6xNFAxKM7:TR?= M2ntUFIyOjh7Mk[3
TAD2 Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;afVExODBizszN NFv5[Vg2KGR? M4TDbGROW09? NG\p[IxKSzVyPkGwNFAh|ryP NGHlNlYzOTJ6OUK2Oy=>
LN229 NHrZSmdCeG:ydH;zbZMhSXO|YYm= NXn2dYhkOC53IN88US=> NES0fI83OCCq MnPOSG1UVw>? M3v0bWF2\22nboTzJIFxd3C2b3flcolkKGWoZnXjeJMhd2ZiZ3XmbZRqdmmk NYK5dodWOjJyNUe5NVQ>
T98G Mk\hRZBweHSxc3nzJGF{e2G7 MVGwMlUh|ryP NWHicFE5PjBiaB?= NIjvVW1FVVOR MULBeYdu\W62czDhdI9xfG:pZX7pZ{Bm\m[nY4TzJI9nKGenZnn0bY5q[g>? M1O5XVIzODV5OUG0
HC11 NX7KT2RqTnWwY4Tpc44hSXO|YYm= MnHiNVAh|ryP M2nmOlI1KGh? MX;EUXNQ M1LQWWlvcGmkaYTzJO6zNWOjc3XpckBidmRiQVTSVEB{gW62aHXzbZM> MUGyNlQzPjZ{MR?=
MOLT-4 M{T2XWN6fG:2b4jpZ{BCe3OjeR?= NYD6eHk4OTBizszN NIXYZ|M1QCCq M3;YemROW09? Mn7XTWM2OD1zLkhihKnPxE1? MnzGNlI3OTR{NEO=
CEM-R M1XZcGN6fG:2b4jpZ{BCe3OjeR?= NFTrZ2wyOCEQvF2= M{n0SFQ5KGh? M{\Jd2ROW09? NF\YR4dKSzVyPUOuN-KBkc7:TR?= MkWzNlI3OTR{NEO=
CEM-S MkTRR5l1d3SxeHnjJGF{e2G7 NInyfFgyOCEQvF2= MWi0PEBp M2SzVmROW09? MXrJR|UxRTVwMfMAje69VQ>? Mo\LNlI3OTR{NEO=
MOLT-4 NXHkR2lITnWwY4Tpc44hSXO|YYm= NVzLOIZnOTBizszN MVeyOEBp M{n1VWROW09? NF7RZZVDdG:la4OgZ4VtdHNiaX6geIhmKEdyL1exJJBp[XOnIH;mJJRp\SClZXzsJIN6[2yn M{LiUVIzPjF2MkSz
MOLT-4 NUnHUVVUTnWwY4Tpc44hSXO|YYm= Mn;wOQKBkc7:TR?= Mn;hOEBp MYfEUXNQ MlfSTY5kemWjc3XzJJRp\SCjbX;1cpQhd2ZiY3zlZZZm\CCOQ{PBM2ItKGFid3XscE1me3SjYnzpd4hm\CCjdYTvdIhi\3libXHyb4Vz MkPhNlI3OTR{NEO=
CEM-R NVPIb3NbTnWwY4Tpc44hSXO|YYm= M3v3WFTjiIoQvF2= NFy0OpY1KGh? MUDEUXNQ NWDLeYttUW6lcnXhd4V{KHSqZTDhcY92dnRib3[gZ4xm[X[nZDDMR|RCN0JuIHGge4VtdC2nc4ThZoxqe2inZDDheZRweGijZ4mgcYFzc2W{ M1m4ZVIzPjF2MkSz
CEM-S M3y3fWZ2dmO2aX;uJGF{e2G7 NIK1cYw16oDLzszN MnvPOEBp NW\6[oR3TE2VTx?= NFnHPVhKdmO{ZXHz[ZMhfGinIHHtc5VvfCCxZjDjcIVifmWmIFzDOWEwSixiYTD3[YxtNWW|dHHicIl{cGWmIHH1eI9xcGGpeTDtZZJs\XJ? MkfrNlI3OTR{NEO=
HepG2 cell NFjyT2xMcW6jc3WgRZN{[Xl? M1jR[FIxKM7:TR?= MXiyOEBp MXvEUXNQ M3LlW2Rwf26{ZXf1cIF1\XNidHjlJJBpd3OyaH;yfYxifGmxbjDv[kBCU1R? Mnz2NlM4QTd|MUm=
HepG2 cell MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fyWVMxKM7:TR?= M3\OfVI1KGh? MVnEUXNQ M2HQN2lvcGmkaYTzJINmdGxiZ4Lve5Rp NI\rSpczOzd7N{OxPS=>
HepG2 cell MnXwRZBweHSxc3nzJGF{e2G7 MlnwNlAh|ryP MWeyOEBp MYPEUXNQ MlPTTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NW\pSllLOjN5OUezNVk>
GEO Mn;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{O2[|UxOCCwTR?= MYi3NkBp Mn;LSG1UVw>? MUXJcohq[mm2czDj[YxtKGe{b4f0bC=> NHyzNGczPDV6MUKzNS=>
CNE-1 M2TNe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7yNWsyOCEQvF2= NUXGTGRPQTZiaB?= MlTuSG1UVw>? Mnj0TWM2OD1{Lkm2JO69VQ>? NHS5cXEzPTN|NkmyOS=>
CNE-2 Mlz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPlVpNMOTBizszN NUO5flZoQTZiaB?= NH3SPWRFVVOR NWTiXG1xUUN3ME20MlU{KM7:TR?= MlGzNlU{OzZ7MkW=
HONE-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XMN|ExKM7:TR?= NGDkN2s6PiCq MXTEUXNQ MkfjTWM2OD1|LkO3JO69VQ>? M3HXV|I2OzN4OUK1
SUNE-1 NXn2ZnZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTnR5NPOTBizszN NVPZcZFiQTZiaB?= M2L4N2ROW09? Mn70TWM2OD1yLkWyJO69VQ>? MXyyOVM{Pjl{NR?=
CNE-2 NHPCc2xHfW6ldHnvckBCe3OjeR?= MXOxNEDPxE1? M2XRVVQ5KGh? M2XpZWROW09? MoPoTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDheEBIOQ>? M1z5TFI2OzN4OUK1
HONE-1 NILTTIlHfW6ldHnvckBCe3OjeR?= NVfpN|NkOTBizszN NUnZUndwPDhiaB?= MVHEUXNQ MmrDTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDheEBIOQ>? NIX4cGgzPTN|NkmyOS=>
NEC8 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwMEm2OVEh|ryP MlPEV2FPT0WU
P12-ICHIKAWA MoTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXixZmtDUUN3ME2wMlEyPjJizszN M3zTXHNCVkeHUh?=
MDA-MB-175-VII NYDJPVFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwMUO3N|gh|ryP M2PXVHNCVkeHUh?=
AsPC-1 NVfLUnZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwMkKxNlIh|ryP NFTqbHVUSU6JRWK=
T47D MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jFR2lEPTB;MD6yPFI2KM7:TR?= NWf5fHBjW0GQR1XS
HH NWrHbFROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzUbIVvUUN3ME2wMlMxOjh|IN88US=> MUPTRW5ITVJ?
MOLT-16 NIXQRo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\Vd2tKSzVyPUCuN|A{OiEQvF2= NF7GU|VUSU6JRWK=
ES5 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTBwM{S0OVUh|ryP NHjofHhUSU6JRWK=
RS4-11 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\JVZNQUUN3ME2wMlM1PjFizszN NWnSdJFvW0GQR1XS
KARPAS-45 MnzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PtemlEPTB;MD6zO|MzOSEQvF2= MV3TRW5ITVJ?
NCI-H720 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nIUGlEPTB;MD6zO|Y4QSEQvF2= M1jXeHNCVkeHUh?=
H9 NFzndFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4r4UWlEPTB;MD6zPFg5OyEQvF2= MXLTRW5ITVJ?
EFM-19 M1zvc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4n6O2lEPTB;MD60OFAyKM7:TR?= MXLTRW5ITVJ?
SBC-1 NFexeXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvwZ|FIUUN3ME2wMlQ1ODN3IN88US=> MVXTRW5ITVJ?
A4-Fuk M3TPNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3VPIpKSzVyPUCuOFY5PjhizszN MnnWV2FPT0WU
NCI-H1563 NYXiTXRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfX[YtnUUN3ME2wMlQ5OTh7IN88US=> NYP1ZmpOW0GQR1XS
HCC1419 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfUXJFKSzVyPUCuOFg5QTJizszN M4LtOHNCVkeHUh?=
H-EMC-SS MlK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTNTWM2OD1yLkS5PVM6KM7:TR?= M{DPWnNCVkeHUh?=
BHT-101 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\3NpI3UUN3ME2wMlUzQTZzIN88US=> NY[ycpRIW0GQR1XS
IGROV-1 NWTjTYN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwNUWyOFkh|ryP M{PEW3NCVkeHUh?=
HGC-27 M{KyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwNU[3PFMh|ryP NYfRVYJsW0GQR1XS
MDA-MB-361 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTUb4hKSzVyPUCuOVc4PjFizszN M2DLVnNCVkeHUh?=
KE-37 MlvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PBTmlEPTB;MD61PFI3KM7:TR?= MUXTRW5ITVJ?
HCC70 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXUcVBKSzVyPUCuOVk5OjdizszN MYDTRW5ITVJ?
LNCaP-Clone-FGC MmG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTaTWM2OD1yLk[xNFQ5KM7:TR?= M4LTSHNCVkeHUh?=
HAL-01 NYftXph7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPmTWM2OD1yLk[yNVMh|ryP NWDXboxSW0GQR1XS
HT MnriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnFe49KSzVyPUCuOlMzOzlizszN M{L4UXNCVkeHUh?=
MDA-MB-415 MnjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwNkO2NlYh|ryP M3;0bXNCVkeHUh?=
NOS-1 NHX3NlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwNkO3NlMh|ryP MlHmV2FPT0WU
DU-145 NIHicpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwNkS3OFUh|ryP MU\TRW5ITVJ?
OCUB-M MmHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwN{C5OlYh|ryP NYe3S2FvW0GQR1XS
VA-ES-BJ M1z2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojvTWM2OD1yLkezNFI2KM7:TR?= MVTTRW5ITVJ?
J-RT3-T3-5 M3f3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPa[oxKSzVyPUCuO|Q1ODNizszN M4TaRnNCVkeHUh?=
MOLT-4 NHTp[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHGVJpKSzVyPUCuPFA2QDJizszN Ml7DV2FPT0WU
NB7 NHqw[FFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXNTWM2OD1yLkiyOFEyKM7:TR?= NXPtNlVRW0GQR1XS
L-363 NGjSe3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljrTWM2OD1yLkizOFQzKM7:TR?= NHr2TXdUSU6JRWK=
NKM-1 NHjZZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrtbXh1UUN3ME2wMlg3OjV|IN88US=> MWDTRW5ITVJ?
HOP-92 NXHOOoU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLqTWM2OD1yLki3NlI{KM7:TR?= MVzTRW5ITVJ?
OAW-42 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTPOWFqUUN3ME2wMlg5PzJizszN M3v5b3NCVkeHUh?=
HuO9 M{LCT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoKxTWM2OD1yLkmyO|UyKM7:TR?= NEnISHZUSU6JRWK=
MFE-280 MmTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwOU[0OlUh|ryP MkS0V2FPT0WU
EM-2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwOUe5N|kh|ryP MVPTRW5ITVJ?
NCI-H520 M4Dzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTCTWM2OD1yLkm4OVkzKM7:TR?= M1zhSnNCVkeHUh?=
LB2241-RCC NVfkbFVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrZdVNKSzVyPUCuPVk4OzRizszN M1LhdnNCVkeHUh?=
SK-NEP-1 MnX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlm4TWM2OD1zLkG0OFg2KM7:TR?= NYfzfY17W0GQR1XS
LXF-289 NWGxc2VRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHRPVJtUUN3ME2xMlE4OTV4IN88US=> NU\nWVU6W0GQR1XS
EPLC-272H NWewNYZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITzXpdKSzVyPUGuNVczPTZizszN M{nOXXNCVkeHUh?=
COLO-684 NV7qVnlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPmem9KSzVyPUGuNlM4OjVizszN MWHTRW5ITVJ?
ES1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7OTWM2OD1zLkK0NFY2KM7:TR?= MWXTRW5ITVJ?
DOHH-2 M{[2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXMTWM2OD1zLkK4NlA{KM7:TR?= MYPTRW5ITVJ?
CTB-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHCTWM2OD1zLkK4PVkh|ryP NICwd45USU6JRWK=
G-401 M3;v[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfne2xjUUN3ME2xMlI6Pzl3IN88US=> NYm1[5B2W0GQR1XS
LoVo MmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTiXlBKSzVyPUGuN|I2OzRizszN MVXTRW5ITVJ?
Ramos-2G6-4C10 NGHPTWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPXcZJKUUN3ME2xMlM{PzBzIN88US=> NX3WWFd4W0GQR1XS
MFM-223 Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\ZZodtUUN3ME2xMlM1PDZzIN88US=> MmXSV2FPT0WU
PA-1 MkPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnIfJRCUUN3ME2xMlM2OjZ3IN88US=> M{H1fXNCVkeHUh?=
697 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfNV3NKSzVyPUGuN|c3OTZizszN MnuwV2FPT0WU
QIMR-WIL MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfBNXM{UUN3ME2xMlQ6OTF4IN88US=> M3rlVHNCVkeHUh?=
HOS MlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnsTWM2OD1zLkS5OVU5KM7:TR?= NVXjZ3dbW0GQR1XS
DMS-273 Mlz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrFdGlzUUN3ME2xMlUyQTV7IN88US=> M4XqOHNCVkeHUh?=
ME-180 MnjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXL0OY5lUUN3ME2xMlU3QDlzIN88US=> NX2zR243W0GQR1XS
HCC2218 MoC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYq0eJQ{UUN3ME2xMlY5OjJ3IN88US=> NGjHOldUSU6JRWK=
CAL-54 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTFwN{GyOFIh|ryP MVzTRW5ITVJ?
OMC-1 M2W2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2OzeGlEPTB;MT63OFY4PyEQvF2= NFPldYNUSU6JRWK=
COR-L105 MnfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTFwN{m3N|ch|ryP Mo\yV2FPT0WU
BV-173 MnzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkX2TWM2OD1zLkixNFc1KM7:TR?= MnXSV2FPT0WU
RKO MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DBN2lEPTB;MT64O|ExOSEQvF2= MmfkV2FPT0WU
SNU-387 Moi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTFwOEi0NFYh|ryP NV3oR4NUW0GQR1XS
SW1088 MkfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWL6SHA{UUN3ME2xMlk1PjB4IN88US=> MYPTRW5ITVJ?
Hs-578-T MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Dxc2lEPTB;Mj6xNVQ{OyEQvF2= NI\ye3VUSU6JRWK=
OC-314 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;FTWM2OD1{LkG1NFg3KM7:TR?= NWrLWll7W0GQR1XS
RMG-I M4DyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJwMU[zPVgh|ryP M1zoW3NCVkeHUh?=
NCI-H1395 NX\HOZV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTpRlNwUUN3ME2yMlE5ODlzIN88US=> NULMOZFiW0GQR1XS
GAMG NXezO41LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLWS3BKSzVyPUKuNlM5PDVizszN NFywN5FUSU6JRWK=
LB1047-RCC M3XNSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLybFdYUUN3ME2yMlI1OzF5IN88US=> Mn35V2FPT0WU
MN-60 M4XheGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIj0PG9KSzVyPUKuNlk6OjNizszN Ml7ZV2FPT0WU
OAW-28 NGnoWYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXsTWM2OD1{LkK5PVUyKM7:TR?= MU\TRW5ITVJ?
NCI-H2228 MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHkTWM2OD1{LkOxOVUzKM7:TR?= MWfTRW5ITVJ?
ABC-1 MojwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XLPWlEPTB;Mj6zN|I2OyEQvF2= NGfvO3BUSU6JRWK=
LS-513 NHHJSZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXK0S20zUUN3ME2yMlM{PDh2IN88US=> MXrTRW5ITVJ?
KS-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M160[2lEPTB;Mj6zPFE6OSEQvF2= NVfafnpJW0GQR1XS
NB69 NFPqVJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPWVZpKSzVyPUKuN|g6QDNizszN MnHHV2FPT0WU
VM-CUB-1 M{fMXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTJwM{mwPFMh|ryP MmjaV2FPT0WU
D-423MG NGf6coFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTQ[GtKSzVyPUKuOFExPDRizszN MXjTRW5ITVJ?
EW-18 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTJwNEG5N|kh|ryP NFfNWmpUSU6JRWK=
YH-13 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnBNI95UUN3ME2yMlQ3OTV|IN88US=> NFXXXIxUSU6JRWK=
T-24 NEjyVGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTJwNEe4PFEh|ryP MWPTRW5ITVJ?
ES8 NYHLO5hbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrwTWM2OD1{LkS5Nlg4KM7:TR?= M3Thc3NCVkeHUh?=
ES3 M1HKcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LPRmlEPTB;Mj60PVc2QSEQvF2= NGX2T3lUSU6JRWK=
RXF393 Mke2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTJwNkC0PFch|ryP NFfRT|hUSU6JRWK=
RPMI-8226 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3nbXBKSzVyPUKuOlI6PTNizszN MnfmV2FPT0WU
AGS MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXu[4hKSzVyPUKuO|IyOzdizszN NX7Ob5pqW0GQR1XS
HCC1395 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmr4TWM2OD1{Lke1NVg4KM7:TR?= NWXnTY45W0GQR1XS
MV-4-11 MoThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTJwN{WyOlYh|ryP M{fxTHNCVkeHUh?=
A204 NUDnfZdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTJwOEO4O|Ih|ryP MX7TRW5ITVJ?
MCF7 NGe2NohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTJwOE[xNVch|ryP MmPVV2FPT0WU
SNU-423 NVvG[WQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPBW3FbUUN3ME2yMlg6OjR{IN88US=> MWXTRW5ITVJ?
NCI-H1048 NXy1NGkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvsV|VKSzVyPUKuPVY5PjVizszN M2PGb3NCVkeHUh?=
GR-ST NV;MSGRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLIfpJKSzVyPUOuNFQ3OTFizszN M1LMOnNCVkeHUh?=
EoL-1- MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TqemlEPTB;Mz6wO|A2QCEQvF2= NHTXZnpUSU6JRWK=
HuH-7 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXQWFZLUUN3ME2zMlA6PDZ2IN88US=> MWrTRW5ITVJ?
OS-RC-2 M4rPW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPjSpk6UUN3ME2zMlEyOTlizszN M4\ERXNCVkeHUh?=
EW-3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF34S4RKSzVyPUOuNVk2OjlizszN MX\TRW5ITVJ?
NCI-H747 NFfwcWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTNwMkC2PVQh|ryP NIHFbmFUSU6JRWK=
EW-16 NHnsV2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTNwMkG4O|kh|ryP MkPYV2FPT0WU
DOK MmrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnxfZBPUUN3ME2zMlIzQDV7IN88US=> NILBNZhUSU6JRWK=
HCC2157 NX7SfHNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPDUYZKSzVyPUOuN|gyPzlizszN NGnGSpVUSU6JRWK=
OVCAR-3 M2DWR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3HTWM2OD1|LkSwO|g3KM7:TR?= MVLTRW5ITVJ?
NCI-H1623 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4GzbGlEPTB;Mz60NVIzPCEQvF2= MV\TRW5ITVJ?
H4 M16ybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1i3cWlEPTB;Mz60OVYzPiEQvF2= MojxV2FPT0WU
SW1710 NUjNSpJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\JRZJkUUN3ME2zMlQ3Pjd6IN88US=> MnLxV2FPT0WU
RT-112 MnvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vQVWlEPTB;Mz61NlM5QCEQvF2= NVH1e3VEW0GQR1XS
DMS-114 M4\Rbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLnTWM2OD1|Lk[yNlc5KM7:TR?= M3fQUXNCVkeHUh?=
AN3-CA M1vVTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTNwNkK0OVYh|ryP M3vn[3NCVkeHUh?=
KNS-62 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTNwNkOzN|gh|ryP M1LpfXNCVkeHUh?=
SJRH30 MkXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TLe2lEPTB;Mz62PVEzOiEQvF2= MknGV2FPT0WU
G-402 MmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGj1OmhKSzVyPUOuO|A4OTFizszN MoDKV2FPT0WU
MHH-PREB-1 NV3KZopyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fIUGlEPTB;Mz63NlA{QCEQvF2= NIq1OpVUSU6JRWK=
P30-OHK M{Pkemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnlRm5xUUN3ME2zMlgxQTd4IN88US=> Mn3iV2FPT0WU
RVH-421 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXiXlRxUUN3ME2zMlgyPzh6IN88US=> NEj0SZNUSU6JRWK=
LU-134-A Mmn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTNwOEi0Nlgh|ryP Mmf6V2FPT0WU
ECC10 NVTQ[lFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlH4TWM2OD1|LkmzOlIzKM7:TR?= MnWwV2FPT0WU
TGW NHWxOZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\wTWM2OD12LkCyN|A2KM7:TR?= NX;4R4ZSW0GQR1XS
MLMA MoLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTRwMEK5OlYh|ryP MlvuV2FPT0WU
SCC-25 NH6zTHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLRTWM2OD12LkC2OVY3KM7:TR?= M33WNXNCVkeHUh?=
TYK-nu NH\Zem5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTRwMEm1N|Qh|ryP NEGyZ2NUSU6JRWK=
LAMA-84 NED3SmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIOwb2VKSzVyPUSuNVQyQTFizszN M1vzUnNCVkeHUh?=
Calu-3 NI\aNVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGD4eJlKSzVyPUSuNlQ1OTZizszN NFrP[3JUSU6JRWK=
NCI-H460 Ml7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXUUVBKSzVyPUSuNlY1PDNizszN M1excnNCVkeHUh?=
EGI-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDMelA{UUN3ME20MlM4Pzd6IN88US=> MXzTRW5ITVJ?
NCI-H292 Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXryZYZrUUN3ME20MlM5OTR4IN88US=> NVr2ZlgyW0GQR1XS
HCE-T MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDkSpZKSzVyPUSuOFE2PzlizszN M3:4OXNCVkeHUh?=
EW-11 M{PkfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XERmlEPTB;ND60NVg{QCEQvF2= MV\TRW5ITVJ?
ATN-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHPTWM2OD12LkS0N|A1KM7:TR?= MVPTRW5ITVJ?
NB5 M2fRS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\lOodKSzVyPUSuOVM3QTdizszN NF25cIlUSU6JRWK=
KLE M2ru[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonKTWM2OD12LkewNVk5KM7:TR?= MlHWV2FPT0WU
CAL-39 NYnYPVRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvjTWM2OD12LkeyNVQ3KM7:TR?= NGX6NXlUSU6JRWK=
TI-73 M4DVXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTlTWM2OD12LkiwOlA6KM7:TR?= Mm\5V2FPT0WU
HO-1-N-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDwUZNKSzVyPUSuPVQzKM7:TR?= M2HTTXNCVkeHUh?=
786-0 M2m2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1P6RmlEPTB;ND65OFY4OyEQvF2= MVHTRW5ITVJ?
SK-N-DZ NW\sbGF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rv[GlEPTB;ND65OlE1OiEQvF2= MULTRW5ITVJ?
NCI-H446 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrtTWM2OD13LkKwNFA6KM7:TR?= NH;IfZRUSU6JRWK=
ETK-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTVwMkGxOlUh|ryP MU\TRW5ITVJ?
BT-20 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3H1WWlEPTB;NT6yNVM2OyEQvF2= M{P3OXNCVkeHUh?=
MEL-HO M{PLPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTVwM{ezN|Yh|ryP MXrTRW5ITVJ?
CAL-27 NYjzTJJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4q0cWlEPTB;NT60OlM{QSEQvF2= M13uZnNCVkeHUh?=
SW872 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTVwNUm0Nlgh|ryP NYXydZVXW0GQR1XS
RPMI-2650 MmDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LNNGlEPTB;NT62OlE6QSEQvF2= NE\Oc|hUSU6JRWK=
PFSK-1 M2DTd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrMTWM2OD13LkeyO|MzKM7:TR?= MXLTRW5ITVJ?
SF295 NUe5e|U1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTVwOEC2N|Mh|ryP MlnaV2FPT0WU
Becker MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTVwOE[0O|Ih|ryP M4jNWXNCVkeHUh?=
Saos-2 MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPIOVVKSzVyPUWuPFY2OyEQvF2= MVfTRW5ITVJ?
SK-OV-3 NFjLXJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTVwOUm4NVYh|ryP MXnTRW5ITVJ?
VMRC-RCZ NF;WV2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfTTWM2OD14LkC4O|c{KM7:TR?= NIL2UY1USU6JRWK=
EW-22 NWnwVI92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXQO5lKSzVyPU[uNVk3PDlizszN NXHxVHVFW0GQR1XS
BT-474 M4jBbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTZwMkOzJO69VQ>? M3To[nNCVkeHUh?=
BFTC-909 NY\mO4hUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlG1TWM2OD14LkOwN|Q2KM7:TR?= NGWzR|NUSU6JRWK=
NB12 NFzR[WFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHVU5NqUUN3ME22MlM6ODdzIN88US=> MmeyV2FPT0WU
D-263MG M{n3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV2xbYFoUUN3ME22MlQ2OTZ7IN88US=> NIXMVmlUSU6JRWK=
SNB75 NGn1eYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTZwNkCxOFMh|ryP NWP5NJAxW0GQR1XS
A704 NF\BPFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIC3XndKSzVyPU[uOlMxPiEQvF2= MlLLV2FPT0WU
NCI-H1693 NXLVcJI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrOPVhNUUN3ME22MlY{PjB2IN88US=> MmO0V2FPT0WU
LN-405 Mlu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HTVmlEPTB;Nj63PVY4OiEQvF2= MkTFV2FPT0WU
CHL-1 M4nEOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTZwOECwO|kh|ryP NInBTmxUSU6JRWK=
A498 NHvQNGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPpdW86UUN3ME22MlgyQTZzIN88US=> NGjreoFUSU6JRWK=
TE-12 NIHIeZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoexTWM2OD14LkizPFE4KM7:TR?= NXL3[YNPW0GQR1XS
TE-6 NXPFbY43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPiTWM2OD14LkmzNFM5KM7:TR?= MlTuV2FPT0WU
AU565 MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfOTWM2OD14Lkm2PVU4KM7:TR?= MWTTRW5ITVJ?
RD MojyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTZwOUiyPFQh|ryP M3fhTnNCVkeHUh?=
SW1463 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;jWFFLUUN3ME23MlEyOTZ6IN88US=> MVTTRW5ITVJ?
LU-99A NI[2T4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHL1dINKSzVyPUeuNVQ{OjJizszN M3jj[XNCVkeHUh?=
NCI-H28 MljhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLoUWFIUUN3ME23MlI6OjRizszN MYLTRW5ITVJ?
MC-IXC NX3XSmQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorzTWM2OD15LkS4OVc3KM7:TR?= MUnTRW5ITVJ?
GP5d NWrrWHJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTdwNEi3OlQh|ryP Mk\IV2FPT0WU
GB-1 NULLe2hwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPhR|M{UUN3ME23MlU1QDB2IN88US=> MoLaV2FPT0WU
CAL-33 M3\Se2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTdwNk[yN|Mh|ryP NIWyb41USU6JRWK=
MSTO-211H MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;sem01UUN3ME23MlY4OzN4IN88US=> MlzJV2FPT0WU
TE-5 NHjX[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTJblR4UUN3ME23Mlc6OzN2IN88US=> M{X4NHNCVkeHUh?=
D-566MG NUP3Vo46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPQbFlNUUN3ME24MlA1PDJ7IN88US=> Mn35V2FPT0WU
JVM-3 NFT0ZZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37MSWlEPTB;OD6xOVI3QCEQvF2= MV\TRW5ITVJ?
T98G M2nKU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXhdHhKSzVyPUiuNVgxPjdizszN MVXTRW5ITVJ?
HCC1954 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3HTWM2OD16LkS1NVA1KM7:TR?= NXf0SpVsW0GQR1XS
SF126 NEjqZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRThwNEW5N|Yh|ryP NWfYT4s3W0GQR1XS
LB996-RCC MoD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLV[JVQUUN3ME24MlU{OjV5IN88US=> Mme3V2FPT0WU
SKG-IIIa MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXQXWdEUUN3ME24MlY{ODZ7IN88US=> NEjM[mJUSU6JRWK=
NCI-SNU-1 M2PKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4K5SmlEPTB;OD62OFY1OyEQvF2= M3e5VnNCVkeHUh?=
LB771-HNC Mn\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRThwNkS2PVYh|ryP MU\TRW5ITVJ?
SCC-4 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrRe5FKSzVyPUiuOlgzOTlizszN NV3lb2F[W0GQR1XS
CAMA-1 M17wUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXhOHRKSzVyPUiuO|cyPDZizszN MnvZV2FPT0WU
D-502MG MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnrb|VKSzVyPUiuO|g3OjlizszN NH7iO5FUSU6JRWK=
ESS-1 M3OzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonKTWM2OD16Lki4O|A1KM7:TR?= M{TUcHNCVkeHUh?=
HEC-1 MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjY[VVKSzVyPUiuPFk5PjZizszN M2fHdnNCVkeHUh?=
NB10 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljvTWM2OD17LkCyNlI1KM7:TR?= NWL1[lltW0GQR1XS
8505C MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XjXWlEPTB;OT6wOFI{OiEQvF2= NE\QdpFUSU6JRWK=
EFO-27 NITUUoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mle1TWM2OD17LkG2OFEzKM7:TR?= NI\DSHJUSU6JRWK=
HN M3nrdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLTTWM2OD17LkG2OlI5KM7:TR?= NYfFWnlUW0GQR1XS
DSH1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmr6TWM2OD17LkKwPFch|ryP MYTTRW5ITVJ?
NBsusSR MnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILoO25KSzVyPUmuNlc1ODJizszN NVLhc4dRW0GQR1XS
LS-123 M4nxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHmTWM2OD17LkOxO|YyKM7:TR?= NEPCdm9USU6JRWK=
SHP-77 M3fPN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfleXZKSzVyPUmuN|k6OzVizszN M{fLfnNCVkeHUh?=
ACN NG\OWZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\WWnNIUUN3ME25MlU{Ojd5IN88US=> M17iVnNCVkeHUh?=
U251 Ml3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37xb2lEPTB;OT62OVU1PCEQvF2= NU\qPJJuW0GQR1XS
A431 Mle2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjxbYZmUUN3ME25MlgxOjN6IN88US=> MXjTRW5ITVJ?
5637 M1zzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTlwOES5PFQh|ryP NEHXdnZUSU6JRWK=
MDA-MB-157 NGPsWZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HheWlEPTB;OT65Nlg4QCEQvF2= MXnTRW5ITVJ?
A101D M3OzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTlwOUm5O|Qh|ryP Mnq1V2FPT0WU
YKG-1 NH\DeoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTFyLkKwNFYh|ryP NYfje205W0GQR1XS
LAN-6 NHHvWXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHnVGFtUUN3ME2xNE4zOTZ2IN88US=> MYfTRW5ITVJ?
OVCAR-5 MmHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DEcGlEPTB;MUCuNlQ{OyEQvF2= MVXTRW5ITVJ?
A549 NF3TXIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLuSHhmUUN3ME2xNE4{QTd|IN88US=> NIDLXJhUSU6JRWK=
no-11 NH7sTZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn2TYcyUUN3ME2xNE41OzV|IN88US=> NEDWWmJUSU6JRWK=
SF539 NXXXfYJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fr[mlEPTB;MUCuPVA1OSEQvF2= M1XTZnNCVkeHUh?=
A388 MmTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV25TZQ1UUN3ME2xNU4{QDl5IN88US=> M{XmcHNCVkeHUh?=
DEL Ml3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPwNXlKSzVyPUGxMlQzPCEQvF2= Mn60V2FPT0WU
SW954 M{j5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrpW3NKSzVyPUGxMlQ3PjhizszN Ml\RV2FPT0WU
TK10 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjUTWM2OD1zMT61NlcyKM7:TR?= MXvTRW5ITVJ?
SW756 NVHmUolET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGD4e|NKSzVyPUGxMlUzQTRizszN NYn1XJVJW0GQR1XS
PC-3 MlzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTFzLkW3OlQh|ryP MmXRV2FPT0WU
ONS-76 NV:0NGc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXLfZozUUN3ME2xNU43OzZizszN NHrkNpZUSU6JRWK=
A427 MmXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\qTWM2OD1zMT63NFk{KM7:TR?= NV7TWmQxW0GQR1XS
MEG-01 NV[0NlU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnZNm1KSzVyPUGxMlc2ODlizszN NX\TTnpoW0GQR1XS
BB30-HNC M3nXcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjye49KSzVyPUGxMlc6QDJizszN NYP5TW5yW0GQR1XS
NCI-H1299 M2rye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPFfWJXUUN3ME2xNU45ODl|IN88US=> MmjBV2FPT0WU
GCT Ml\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofHTWM2OD1zMT64NlI5KM7:TR?= NI\6cHFUSU6JRWK=
D-247MG MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVn5eIZ3UUN3ME2xNU46PjZ|IN88US=> M2X3[HNCVkeHUh?=
CFPAC-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmmwTWM2OD1zMT65O|gzKM7:TR?= MnvRV2FPT0WU
EKVX NVLuNZY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTmXVdEUUN3ME2xNk4xOzF|IN88US=> NFniNY9USU6JRWK=
CAL-51 NHnUcHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPEeWgyUUN3ME2xNk4xPzF4IN88US=> NIf3WmxUSU6JRWK=
BB49-HNC NXzlW2pvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTVTWM2OD1zMj6xNVc4KM7:TR?= NH\TUXNUSU6JRWK=
RPMI-7951 MlTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHPTWM2OD1zMj6xPFU1KM7:TR?= M2Psc3NCVkeHUh?=
RH-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTF{LkKxPFQh|ryP MnL1V2FPT0WU
BCPAP NYHoTW9tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUG4d2dPUUN3ME2xNk41PzR7IN88US=> MUXTRW5ITVJ?
GCIY NG\0[ZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzLNnBKSzVyPUGyMlUzODlizszN MVLTRW5ITVJ?
KNS-81-FD MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTF{LkW4Olkh|ryP NFSwWWlUSU6JRWK=
KYSE-140 M1;Vb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjQU3RXUUN3ME2xNk45PTl3IN88US=> NWqzeIZwW0GQR1XS
Ca-Ski NF\iTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTF{LkmwOFEh|ryP NHv3WHVUSU6JRWK=
TGBC1TKB NVW2ZYFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTF{LkmxNVUh|ryP M3vuU3NCVkeHUh?=
HCC1187 NHj1SYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPZS3h3UUN3ME2xN{4yQTF{IN88US=> MlzqV2FPT0WU
SJSA-1 MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELVS2dKSzVyPUGzMlI{OjdizszN MmTEV2FPT0WU
CTV-1 MnT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jjc2lEPTB;MUOuN|Q2KM7:TR?= MUTTRW5ITVJ?
WM-115 NELRUIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTF|Lk[0PFMh|ryP Mn;oV2FPT0WU
CHP-212 NXrQSmlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjtb2dKSzVyPUGzMlk4OzlizszN MoLwV2FPT0WU
SCC-15 M2raeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrjTWM2OD1zMz65O|c2KM7:TR?= NYnvR|ZxW0GQR1XS
BPH-1 Ml21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFe1WXRKSzVyPUG0MlE3PjRizszN NIjjUo5USU6JRWK=
SW780 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4P1fWlEPTB;MUSuOVAzPSEQvF2= MmTTV2FPT0WU
NCI-H2291 M4S2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HMXGlEPTB;MUSuOVg4QCEQvF2= MoXtV2FPT0WU
JEG-3 Mo[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;PTWM2OD1zND62N|I3KM7:TR?= MnTvV2FPT0WU
CAL-120 NGHXTmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPWXVhmUUN3ME2xOE44ODJ5IN88US=> NEPNTmVUSU6JRWK=
NCI-H23 NYSySHNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTnZnVKSzVyPUG0Mlc6QTdizszN MkTXV2FPT0WU
MS-1 NVv4XFFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\meGdKSzVyPUG0Mlk3OTFizszN MnrNV2FPT0WU
PC-14 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLjTWM2OD1zND65OlU1KM7:TR?= NGqwRXRUSU6JRWK=
D-283MED MnHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHvTWM2OD1zNT6wNVEyKM7:TR?= MX7TRW5ITVJ?
OE19 MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTF3LkG1OFEh|ryP NX:zSodQW0GQR1XS
CAS-1 NFjTbFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HR[GlEPTB;MUWuOFE5PCEQvF2= MVTTRW5ITVJ?
NCI-H727 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjLXZRKSzVyPUG1MlQzOjFizszN NVjTb21MW0GQR1XS
SiHa NF7aT45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIi1ZmhKSzVyPUG1Mlc2QTRizszN MXPTRW5ITVJ?
BFTC-905 NXTuRVBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjUdHZMUUN3ME2xOU44Pjl2IN88US=> Ml7CV2FPT0WU
MDA-MB-453 NX;XSmVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzhSpFKSzVyPUG2MlE3PDJizszN MkjiV2FPT0WU
HuP-T3 MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTF4Lk[zO|Mh|ryP M1;RW3NCVkeHUh?=
SK-LU-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzQNG9KSzVyPUG2MlY6PTZizszN NI\PWYxUSU6JRWK=
Detroit562 NFfadpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHtTWM2OD1zNj63N|E5KM7:TR?= NXXHRYl3W0GQR1XS
HCC1569 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\sTWM2OD1zNj64N|M4KM7:TR?= MYjTRW5ITVJ?
SK-MES-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlmyTWM2OD1zNj64OFE6KM7:TR?= MkPwV2FPT0WU
BB65-RCC NVr4eJM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrOSJVYUUN3ME2xO{4xPDd7IN88US=> NHzTeJpUSU6JRWK=
LOXIMVI NIHheo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mki2TWM2OD1zNz6wO|A4KM7:TR?= Ml64V2FPT0WU
SW1783 NX\UUIY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlT3TWM2OD1zNz6xNlgh|ryP NHzlfXVUSU6JRWK=
NH-12 M3flT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHReHVKSzVyPUG3MlM{ODNizszN MYDTRW5ITVJ?
UACC-257 NXHMUldlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnQTWM2OD1zNz61OVEzKM7:TR?= NH20WZhUSU6JRWK=
KOSC-2 NX7VUnB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPpTWM2OD1zNz62O|U4KM7:TR?= MX\TRW5ITVJ?
KG-1 NHK4RllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTF5Lk[5N|ch|ryP NHTR[JlUSU6JRWK=
M059J M3voU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTF5LkewN{DPxE1? M3rQfXNCVkeHUh?=
MHH-NB-11 NWW4ZWFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTF5Lkm2O|Mh|ryP NFS3UnRUSU6JRWK=
EW-1 M3jqXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHaTWM2OD1zOD6xN|gzKM7:TR?= Mn73V2FPT0WU
CAL-85-1 NETNZ2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zTS2lEPTB;MUiuNlM2PyEQvF2= NXe1VFNtW0GQR1XS
639-V MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTF6LkOzOVQh|ryP NF3XbnZUSU6JRWK=
C32 M1nWO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTF6LkS3Nlch|ryP Mne3V2FPT0WU
KM-H2 MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XBfGlEPTB;MUiuOVI{OiEQvF2= M3roOXNCVkeHUh?=
A253 NUnESGJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLvdnY5UUN3ME2xPE44Ojh4IN88US=> NEfNeVFUSU6JRWK=
NCI-N87 Mo\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGmzcFlKSzVyPUG4MlkxODhizszN M1PDUHNCVkeHUh?=
8-MG-BA NFr5[YdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTF7LkC2OFYh|ryP NIrQbnZUSU6JRWK=
GI-ME-N MkX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TWdGlEPTB;MUmuNVU1PiEQvF2= M4DZbnNCVkeHUh?=
8305C MnnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTF7LkKyPFYh|ryP MWjTRW5ITVJ?
TE-8 NIXofm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\DboRKSzVyPUG5MlMxOjRizszN NI[zXIpUSU6JRWK=
KYSE-270 NVy5TpBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLJTGJKSzVyPUKwMlAzOTdizszN MlHaV2FPT0WU
HL-60 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTJyLkC5OFEh|ryP MlPvV2FPT0WU
Mo-T MkPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXGzeXFVUUN3ME2yNE4yPjZ3IN88US=> NH\MVIVUSU6JRWK=
NCI-H1355 NInDT2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjRfZZKSzVyPUKwMlM{PzRizszN M4LjWXNCVkeHUh?=
HT-1080 MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XROGlEPTB;MkCuOVQ6PyEQvF2= MXHTRW5ITVJ?
MIA-PaCa-2 MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoX1TWM2OD1{MD62PFg{KM7:TR?= NUftNnp1W0GQR1XS
NCI-H441 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHYTWM2OD1{MD63N|c6KM7:TR?= NFewfYZUSU6JRWK=
LCLC-97TM1 MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPIOVhVUUN3ME2yNE45OTN2IN88US=> MVjTRW5ITVJ?
HT-3 NVnkW|hqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrkOpFKSzVyPUKxMlU3OzFizszN NXPPRYJUW0GQR1XS
22RV1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTJzLkW2PFUh|ryP MofNV2FPT0WU
LK-2 MlPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{SxemlEPTB;MkGuOVk2OyEQvF2= NV;IO5ZVW0GQR1XS
CW-2 M1rseWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWG2emt1UUN3ME2yNU43ODZ7IN88US=> NYXQbVBsW0GQR1XS
KYSE-510 Mlf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;Ec|B5UUN3ME2yNU43ODl3IN88US=> NF\rPFVUSU6JRWK=
CGTH-W-1 NGrScJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTEOFBKSzVyPUKxMlcyPjZizszN MXzTRW5ITVJ?
NCI-H661 MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTJ{LkCzOEDPxE1? NI\jWpJUSU6JRWK=
KU-19-19 NXfFPFRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojzTWM2OD1{Mj6xOlk4KM7:TR?= Mo\CV2FPT0WU
NCI-H2122 NFm3SIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPWVpdKSzVyPUKyMlI1OzJizszN NXjYdlRCW0GQR1XS
NCI-H526 NVjFVHFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\tdGN1UUN3ME2yNk4{QDl3IN88US=> NXWyeVRoW0GQR1XS
NCI-H1650 NX73[ZF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILMfpZKSzVyPUKyMlc3PCEQvF2= Mm\PV2FPT0WU
AM-38 NYn6bVZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDXZZlKSzVyPUKyMlg3QDlizszN NVHEZog{W0GQR1XS
NCI-H2405 NU\VbVJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjFOG9KSzVyPUKzMlI2OzNizszN NH;hWJFUSU6JRWK=
M14 MlztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7hO4dKSzVyPUKzMlQxQDhizszN M2TVPXNCVkeHUh?=
ES4 NHXn[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk[3TWM2OD1{Mz60NlMzKM7:TR?= M1L1NnNCVkeHUh?=
DJM-1 NX7XVGJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXPTWM2OD1{Mz61NlM1KM7:TR?= NIXl[ZlUSU6JRWK=
S-117 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3G5XmlEPTB;MkOuO|Y2OSEQvF2= MWXTRW5ITVJ?
MZ2-MEL NFP1VXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHS5VGVKSzVyPUKzMlc4PTlizszN MoG0V2FPT0WU
SK-MEL-2 NFXm[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLSTWM2OD1{Mz64NVM{KM7:TR?= MVvTRW5ITVJ?
HCC1806 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHHTWM2OD1{Mz64O|A6KM7:TR?= MWTTRW5ITVJ?
NMC-G1 NHTo[HhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;nT4ZKSzVyPUK0MlIzOjZizszN NYTwT2c2W0GQR1XS
DK-MG NVKwblF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJ2LkK5OEDPxE1? MXLTRW5ITVJ?
SK-N-FI NHj2TYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfuNXNxUUN3ME2yOE4{OzB{IN88US=> NH\Z[mZUSU6JRWK=
KINGS-1 Ml\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\UTWM2OD1{ND60PFc1KM7:TR?= M3vCbXNCVkeHUh?=
HCC2998 NUPXUXg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvtZXJOUUN3ME2yOE41QDh3IN88US=> Mn;XV2FPT0WU
ALL-PO M3j2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3G[FdKSzVyPUK0MlYyQSEQvF2= MXrTRW5ITVJ?
MPP-89 NUjsSGRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTJ3LkC0OVgh|ryP M1vucnNCVkeHUh?=
NCI-H2342 M1\yUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2T0WGlEPTB;MkWuNVk2OyEQvF2= M2TZSnNCVkeHUh?=
TE-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jNe2lEPTB;MkWuN|U3OyEQvF2= MX7TRW5ITVJ?
RH-18 M3;KOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vSW2lEPTB;MkWuOVkyQCEQvF2= NVjxVG9iW0GQR1XS
HT-1376 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHS[XROUUN3ME2yOU43PDZ3IN88US=> M2HvbnNCVkeHUh?=
U-2-OS NWWzdoxIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjRXnFFUUN3ME2yOU43QDh6IN88US=> MkfKV2FPT0WU
BT-549 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37EWWlEPTB;MkWuPVAyOSEQvF2= MVrTRW5ITVJ?
NCI-H1755 M3u5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHP1bpBKSzVyPUK1Mlk6PDVizszN MkSxV2FPT0WU
EW-13 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHUTWM2OD1{Nj6wNlc1KM7:TR?= M3vTS3NCVkeHUh?=
NB13 MnrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJ4LkC5OFkh|ryP M3flT3NCVkeHUh?=
NUGC-3 NHz3WY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDsTWM2OD1{Nj6yNVA{KM7:TR?= MX\TRW5ITVJ?
GMS-10 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJ4LkKzOVMh|ryP NFLnRYtUSU6JRWK=
CHP-134 MnjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXyTWM2OD1{Nj6zPFY4KM7:TR?= M1WweXNCVkeHUh?=
SW962 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLQTWM2OD1{Nj61NFIyKM7:TR?= M4DJSXNCVkeHUh?=
SNU-449 NIrXXWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfwTWM2OD1{Nz6wPFA{KM7:TR?= NF7oPJVUSU6JRWK=
HuP-T4 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUKxflRtUUN3ME2yO{4xQDd7IN88US=> M{DQWXNCVkeHUh?=
SW948 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPXe2pKSzVyPUK3MlE{PDRizszN NX3DdJRMW0GQR1XS
NCI-H226 M36wdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPsVmVKSzVyPUK3MlQ2PzhizszN MULTRW5ITVJ?
SK-PN-DW NV7vPJdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTJ5Lk[wNVIh|ryP NVjobnNVW0GQR1XS
GI-1 NEHWWGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXz3dVg3UUN3ME2yO{44OjFizszN NX3yb4t7W0GQR1XS
CAL-12T M2W4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFL6dW1KSzVyPUK4MlEyOTJizszN M{ntU3NCVkeHUh?=
YAPC NWLzWIx4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTJ6LkK1OlQh|ryP NVi4cFFMW0GQR1XS
SNU-C2B NGPtblJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETMbHpKSzVyPUK4MlI6PjRizszN MUnTRW5ITVJ?
RCC10RGB NIryR4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fnVmlEPTB;MkiuOVQyPyEQvF2= NITPOJZUSU6JRWK=
ES7 NXn6Xmw5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfTUmNKSzVyPUK5MlE1PjVizszN NEXTdWpUSU6JRWK=
PANC-03-27 NGnjfJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjWTWM2OD1{OT60OFQh|ryP NGrte4hUSU6JRWK=
ES6 MoHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[1UWlEPTB;MkmuPFE2PyEQvF2= NXT2PJJoW0GQR1XS
HT-1197 NIPVWmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DRVmlEPTB;M{CuNFU6QCEQvF2= NUTVVFRoW0GQR1XS
ZR-75-30 MlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mni5TWM2OD1|MD6yN|g{KM7:TR?= MkjKV2FPT0WU
DB NXHRZ4NIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnqTWM2OD1|MD60PVQzKM7:TR?= Mk[5V2FPT0WU
OCI-AML2 MnWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLTTWM2OD1|MT6wOlkh|ryP M3HtN3NCVkeHUh?=
NCI-H2170 MkjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTNzLki1NVYh|ryP NWPTWm1ZW0GQR1XS
IST-MES1 NYrme2FCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLjZ5VNUUN3ME2zNk4zQDl5IN88US=> M2\BR3NCVkeHUh?=
769-P M{\1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTN{LkO2OFEh|ryP M{i0cHNCVkeHUh?=
COR-L23 NWX4[|VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rHNGlEPTB;M{KuPVA4OyEQvF2= NEX0dIVUSU6JRWK=
SW626 NIjWc4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTN|LkG3O|Yh|ryP MUfTRW5ITVJ?
LU-139 Mn\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[5OYx1UUN3ME2zN{43PjB3IN88US=> NFS3fpBUSU6JRWK=
HT-144 MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTN|Lki2N{DPxE1? MVfTRW5ITVJ?
CaR-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTN|Lkm4NlIh|ryP MW\TRW5ITVJ?
OE33 M2fBc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTN2LkK4OVUh|ryP NEPsVmdUSU6JRWK=
COLO-800 NH3tSYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPXemxwUUN3ME2zOE4{PjR5IN88US=> MoTrV2FPT0WU
NB14 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj3TWM2OD1|ND60Olg1KM7:TR?= M1S2TXNCVkeHUh?=
KURAMOCHI MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknWTWM2OD1|Nj6xNVk5KM7:TR?= M2L1SnNCVkeHUh?=
SW48 NYf2NpBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzYdVBIUUN3ME2zOk4zPDd2IN88US=> M{f2W3NCVkeHUh?=
Daoy MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPCOZJKSzVyPUO2MlY2OzhizszN MljmV2FPT0WU
TGBC24TKB NFXNSVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTN4Lk[3JO69VQ>? NIn5[pRUSU6JRWK=
DU-4475 M{Tucmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfPd5E1UUN3ME2zOk46ODN|IN88US=> MY\TRW5ITVJ?
SW1417 NU\pUGlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2X0PGlEPTB;M{iuNFU2OiEQvF2= NWqzZ|RrW0GQR1XS
EFO-21 NVr0SmMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfFTmx7UUN3ME2zPE46OzR7IN88US=> M3H6NnNCVkeHUh?=
MG-63 M13qNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HTS2lEPTB;M{muN|QzPCEQvF2= MnK2V2FPT0WU
LC-2-ad NHmxNnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\2SWlEPTB;M{muOVUyOiEQvF2= NGHJU4JUSU6JRWK=
NOMO-1 NI\4c2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHNV3dKSzVyPUO5MlgzPzRizszN MXXTRW5ITVJ?
COLO-741 Ml60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PndmlEPTB;NECuNVMxPCEQvF2= M{jo[XNCVkeHUh?=
BxPC-3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTRyLkW2PFYh|ryP Mn;4V2FPT0WU
HSC-2 NXOzfXJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moe1TWM2OD12MD65NVE{KM7:TR?= MVvTRW5ITVJ?
UMC-11 MmrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTRzLkK2N{DPxE1? MWHTRW5ITVJ?
HCC1937 NX;EU29[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTR{Lke4OFMh|ryP NID4S2hUSU6JRWK=
Calu-6 NH\uRlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPrTWM2OD12Mz6yN|gzKM7:TR?= Mom1V2FPT0WU
NCI-H1573 M4rXe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHlTXpKSzVyPUSzMlM1PzdizszN M4S3WHNCVkeHUh?=
SK-N-AS NFuxbI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrqcGFKSzVyPUSzMlYxOTlizszN NWnTVW5DW0GQR1XS
PSN1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\1dmlEPTB;NEWuNlU1QCEQvF2= MVfTRW5ITVJ?
TE-11 NXfYeJl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13JWWlEPTB;NEWuOFg1OiEQvF2= NF;0cZdUSU6JRWK=
NCI-H1155 M4jzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF22b|RKSzVyPUS1Mlg6PjdizszN NHP6NGRUSU6JRWK=
KM12 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTR3LkmwO|Yh|ryP NGTsUWZUSU6JRWK=
RO82-W-1 NVH0N5NuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm[zTWM2OD12Nj65PFIzKM7:TR?= NU\IUIJQW0GQR1XS
SW1573 MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnEfpVKSzVyPUS3MlM4OzZizszN NH35[XpUSU6JRWK=
CAKI-1 NIq2copIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fpcGlEPTB;NEiuNlg1PSEQvF2= Mn74V2FPT0WU
U-118-MG M1:wSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zRfWlEPTB;NEiuN|cxOiEQvF2= M4f3RnNCVkeHUh?=
KYSE-520 NI\h[oNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYP3V5lZUUN3ME20PE41ODF4IN88US=> M{DSVXNCVkeHUh?=
HT55 NX7jNFN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTzW5JVUUN3ME20PU4yPDd2IN88US=> MUXTRW5ITVJ?
ChaGo-K-1 NFr5[4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrve4tiUUN3ME20PU41Pzl|IN88US=> Ml\LV2FPT0WU
IA-LM M4\6d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLiTWM2OD13ND62N|IzKM7:TR?= NVu4d2ZXW0GQR1XS
UACC-62 M3ntb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTV3LkGwOFYh|ryP MonYV2FPT0WU
MKN7 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUG5NmFqUUN3ME21Ok4xOjh3IN88US=> NETnXY5USU6JRWK=
HPAF-II M1[zTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fDWmlEPTB;NU[uOFA4OyEQvF2= NGT6eXlUSU6JRWK=
NTERA-S-cl-D1 MnmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\Xc2lEPTB;NUeuO|c5KM7:TR?= NFTJNnRUSU6JRWK=
FTC-133 M1jqPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTV6LkC5Olkh|ryP NWnES3psW0GQR1XS
MHH-ES-1 NXv4U41RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTV6LkS4NVQh|ryP MV;TRW5ITVJ?
JVM-2 M3PFdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37UVmlEPTB;NUiuPVUxPiEQvF2= M2nyXXNCVkeHUh?=
TCCSUP NV;YNodTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7DTWM2OD13OT61Nlc6KM7:TR?= NF7oXGFUSU6JRWK=
COLO-824 MoDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnw[JJKSzVyPU[wMlA4OTlizszN MmfrV2FPT0WU
647-V MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzUTWM2OD14MD6xN|Q4KM7:TR?= MYrTRW5ITVJ?
HD-MY-Z NHrDeXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLOV2c{UUN3ME22NE42Ojl2IN88US=> Mo\EV2FPT0WU
LS-411N M4\rb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULkflBzUUN3ME22NU4{QTB|IN88US=> MYTTRW5ITVJ?
NCI-H596 NG\2ZZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV[0OIRHUUN3ME22Nk44PDl4IN88US=> M2LkeXNCVkeHUh?=
C-33-A M1u2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jTWWlEPTB;NkSuNFk2PyEQvF2= NEi0[mpUSU6JRWK=
BHY NF35OFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:xOphUUUN3ME22OE4yOjR3IN88US=> NI\uXphUSU6JRWK=
KGN NF\EW5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvJTWM2OD14ND61OVE1KM7:TR?= NWn3SG5{W0GQR1XS
NCI-H1092 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn72TWM2OD14NT6wNFk2KM7:TR?= MULTRW5ITVJ?
MZ1-PC MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zr[2lEPTB;NkWuOVY1QSEQvF2= MX;TRW5ITVJ?
LB831-BLC M{X1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTZ3Lki0PFEh|ryP MXvTRW5ITVJ?
SW620 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XlbGlEPTB;Nk[uNlA{QSEQvF2= M1zOd3NCVkeHUh?=
HuO-3N1 M4X6Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDYOGNKSzVyPU[4MlMzOzhizszN MnOxV2FPT0WU
SK-HEP-1 NULkOVBCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TMTmlEPTB;NkmuPVQ5PiEQvF2= NX34PGhRW0GQR1XS
LCLC-103H MoXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13QeGlEPTB;N{CuOlcxPSEQvF2= Mo\rV2FPT0WU
KYSE-70 NIHPdJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVuxb2tuUUN3ME23NE44QDN3IN88US=> NXy3WFFpW0GQR1XS
Mewo MmH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTdzLkWwOUDPxE1? M2X2ZnNCVkeHUh?=
COLO-668 M2\IUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTdzLki0OVEh|ryP NX;pT4E1W0GQR1XS
NCI-H522 M4fsdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnWXYRiUUN3ME23Nk4{PDF|IN88US=> NUO3Oo96W0GQR1XS
NCI-H1437 NYK3VHBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLiTWM2OD15ND60NFQ5KM7:TR?= NGnyR|VUSU6JRWK=
U-266 MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjXcG9kUUN3ME23OU41PTF4IN88US=> MlfXV2FPT0WU
MC116 NVz4TYlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXaTWM2OD15NT61O|A5KM7:TR?= NHrUSnZUSU6JRWK=
PANC-10-05 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3G1Z2lEPTB;N{euOFI1OyEQvF2= NIW3SXpUSU6JRWK=
KYSE-180 NVraWGpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jRT2lEPTB;N{euOVQ2PCEQvF2= M4fiXXNCVkeHUh?=
JAR MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnRTWM2OD15OT6wOVQ3KM7:TR?= NGnWcGtUSU6JRWK=
CAL-62 MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFO2Z29KSzVyPUiwMlA6PSEQvF2= Mnr4V2FPT0WU
A3-KAW NVqybYN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHHd3VKSzVyPUiwMlIyPTRizszN NVnPWYo2W0GQR1XS
PANC-08-13 M2n4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjZOIhKSzVyPUixMlE4PjhizszN MUfTRW5ITVJ?
HSC-3 MmHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[0TWM2OD16Mz6zNFcyKM7:TR?= NH;WXphUSU6JRWK=
HTC-C3 MmLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTh|LkS3NFIh|ryP NHXz[5NUSU6JRWK=
KY821 M1nJZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTh2LkC4PVIh|ryP M1f3d3NCVkeHUh?=
DoTc2-4510 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXqTWM2OD16ND6yNVg2KM7:TR?= MlrkV2FPT0WU
NCI-H1581 Mnm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVr1TINHUUN3ME24OU41PjRzIN88US=> MoG3V2FPT0WU
KARPAS-299 MnnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\wSGlEPTB;OE[uNVk4PyEQvF2= MUXTRW5ITVJ?
IST-MEL1 M3q3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4O4O2lEPTB;OE[uPFg4OiEQvF2= M1HCV3NCVkeHUh?=
KP-N-YS M1rsO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4W3ZmlEPTB;OEmuPVAzQCEQvF2= Mlf2V2FPT0WU
KYSE-410 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DwUGlEPTB;OUGuOFA1OiEQvF2= M1HxSXNCVkeHUh?=
TE-10 Ml\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2f1SmlEPTB;OUGuOVYyOSEQvF2= NH\Yd21USU6JRWK=
SK-MEL-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTl{LkmxNFYh|ryP M2TObHNCVkeHUh?=
COLO-792 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPiTWM2OD17NT6yOVY1KM7:TR?= M4DETnNCVkeHUh?=
SCH NUX6RYtTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFr3V2FKSzVyPUm2MlM5PzdizszN MXnTRW5ITVJ?
NCI-H1792 M{PjeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7xTWM2OD17Nj64PVkzKM7:TR?= MUTTRW5ITVJ?
NCI-H2029 NGXkcGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfwTWM2OD17Nj65OVY3KM7:TR?= NXK3RWMxW0GQR1XS
SW684 M2X0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTl6Lk[2OVQh|ryP M2DHVXNCVkeHUh?=
NCI-H209 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmroTWM2OD1zMECuNVIyKM7:TR?= MYDTRW5ITVJ?
HLE NVnaTZk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTFyNT6yPFIh|ryP MnP0V2FPT0WU
GOTO MkTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Lib2lEPTB;MUC3Mlc4PyEQvF2= MnH6V2FPT0WU
NCI-H1793 NETGeFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHrTWM2OD1zMEmuNlgh|ryP MXPTRW5ITVJ?
D-392MG MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTFzNz6zPVgh|ryP NFrwUJdUSU6JRWK=
SW1990 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHSSWMxUUN3ME2xNlAvQTVzIN88US=> NFXycYlUSU6JRWK=
ML-2 NEPTe2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHiUoVKSzVyPUGyNU43PzZizszN NET5OItUSU6JRWK=
NCI-H2452 M4nMTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2q0Z2lEPTB;MUKyMlIyKM7:TR?= NGfFbo5USU6JRWK=
SK-MEL-30 NEe2XXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnu2TWM2OD1zMkOuNlQ1KM7:TR?= M1rSWHNCVkeHUh?=
SN12C MlLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXMXI5KSzVyPUGyOE4yPzZizszN NXHSVoFyW0GQR1XS
NCI-H1770 MnvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1P1ZmlEPTB;MUK1MlUyPCEQvF2= MWfTRW5ITVJ?
SF268 NYHFe|dTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\qTWM2OD1zMk[uNVU5KM7:TR?= MnPkV2FPT0WU
BALL-1 Mn\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljwTWM2OD1zMk[uNlMh|ryP NHHRXpVUSU6JRWK=
COLO-679 M3\VOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nHZmlEPTB;MUK2Mlc2OyEQvF2= NGnlVGNUSU6JRWK=
A2780 NVzlVG1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTF{OD65PFgh|ryP MYTTRW5ITVJ?
NCI-H1651 NXKzbHEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmD4TWM2OD1zM{GuNlQ{KM7:TR?= MYLTRW5ITVJ?
NCI-H2087 NIPjTo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTF|MT60PFMh|ryP MVXTRW5ITVJ?
U-87-MG MmjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfaTWM2OD1zM{OuOlA1KM7:TR?= MlHnV2FPT0WU
LB2518-MEL NVWye3JYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TBSWlEPTB;MUO1Mlk6OyEQvF2= MkTQV2FPT0WU
HCT-116 MkCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDRVWNNUUN3ME2xN|cvOjF5IN88US=> NIPIZZJUSU6JRWK=
Ca9-22 MnzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDtTWM2OD1zM{muPFM{KM7:TR?= M{\uV3NCVkeHUh?=
COR-L88 NFzBVHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVyzc21JUUN3ME2xOFIvOTRizszN M1ztbHNCVkeHUh?=
CP50-MEL-B NF;6e5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTF2ND61NFEh|ryP MXvTRW5ITVJ?
OVCAR-8 NVf6RoZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPnTWM2OD1zNEWuOlM3KM7:TR?= M37xZ3NCVkeHUh?=
SK-MEL-3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTKTWM2OD1zNEeuPFc5KM7:TR?= MV;TRW5ITVJ?
GT3TKB MmP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfaVIJKSzVyPUG0PU46OjhizszN MVnTRW5ITVJ?
KYSE-450 M2XkU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVX2NoR7UUN3ME2xOVEvPTN7IN88US=> M1TFTHNCVkeHUh?=
CAPAN-1 NWjsV|lNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfCW5hvUUN3ME2xOVMvODZ2IN88US=> NEfCOopUSU6JRWK=
BEN MnfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFf2OVVKSzVyPUG1N{46OjhizszN NYqxfYhwW0GQR1XS
NCI-H1304 NIDRV5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfndmZsUUN3ME2xOVQvPjl2IN88US=> MWLTRW5ITVJ?
KU812 M1zmSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTF3OD62O|Qh|ryP NVPNd3g5W0GQR1XS
Capan-2 NXTnVHJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXmTWM2OD1zNkCuOVU{KM7:TR?= NXyzU3ZJW0GQR1XS
A673 M1nP[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmroTWM2OD1zNkGuO|A2KM7:TR?= NUi4PJczW0GQR1XS
SAS NGL5eIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzXTWM2OD1zNkKuOlc5KM7:TR?= Mn:zV2FPT0WU
NY NGLTcYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ziRmlEPTB;MU[1MlMyPCEQvF2= MUPTRW5ITVJ?
HCE-4 NEPr[ppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHwVJRKSzVyPUG2Ok45PDVizszN MWHTRW5ITVJ?
MDA-MB-231 M{\ZOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvITWM2OD1zN{euOVA{KM7:TR?= MkTkV2FPT0WU
no-10 M{HHXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2e4O2lEPTB;MUe4MlE{PCEQvF2= MXHTRW5ITVJ?
MZ7-mel M2LBO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTF5OD60Olch|ryP NFz3OIZUSU6JRWK=
NCI-H82 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\nVmlEPTB;MUiwMlE3PSEQvF2= NFTKVIhUSU6JRWK=
CAL-72 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rNNGlEPTB;MUi1MlA2PCEQvF2= Mk\XV2FPT0WU
NCI-SNU-5 NIXQ[JhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nzUWlEPTB;MUi2Mlg1KM7:TR?= MnfUV2FPT0WU
OVCAR-4 NWjR[2tOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrkPZZKSzVyPUG4PE4{OzNizszN NYrU[Y9HW0GQR1XS
SCC-9 MkXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnDXnF{UUN3ME2xPVEh|ryP MXLTRW5ITVJ?
KYSE-150 NGW5ZYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTF7MT64PFgh|ryP NXmyUZNTW0GQR1XS
HT-29 NFnQXYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTGTWM2OD1{MEGuNlEzKM7:TR?= M1LGd3NCVkeHUh?=
COLO-678 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rOSGlEPTB;MkCxMlQ2KM7:TR?= MX7TRW5ITVJ?
NCI-H650 MonxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH62b41KSzVyPUKwNk4yODNizszN M2nud3NCVkeHUh?=
HuCCT1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTJyND6yNFgh|ryP MYTTRW5ITVJ?
SW1116 M1XYVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFH1OpZKSzVyPUKwO{4xPzdizszN M2Lnb3NCVkeHUh?=
DBTRG-05MG MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zBU2lEPTB;MkC3MlkxQSEQvF2= MojKV2FPT0WU
SW982 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJyNz65OFgh|ryP NISyfFlUSU6JRWK=
RCM-1 NIq3RWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DxU2lEPTB;MkG0Mlc3OiEQvF2= NIDEepBUSU6JRWK=
COLO-320-HSR NHrBbWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jT[WlEPTB;MkG2MlEzPSEQvF2= M{\w[nNCVkeHUh?=
KNS-42 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoflTWM2OD1{MU[uOVc1KM7:TR?= NHO2dIxUSU6JRWK=
C2BBe1 MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7JNWVKSzVyPUKzNU46ODVizszN MmjLV2FPT0WU
CCRF-CEM M{\QRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFG1Z5NKSzVyPUK0N{44QTVizszN NXrXfFBuW0GQR1XS
SH-4 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2X3e2lEPTB;MkS2MlA6KM7:TR?= MnLxV2FPT0WU
LS-1034 NX;jc5lXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTJ2Nj6yOlYh|ryP NVL2W2pkW0GQR1XS
NCI-H2347 M1jRcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTJ2Nz63NVMh|ryP MnXlV2FPT0WU
RPMI-8866 NGDCTVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2X0NmlEPTB;MkS5MlI4KM7:TR?= MlXyV2FPT0WU
GAK NW\rcJRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Tz[WlEPTB;MkWzMlAxOiEQvF2= M{nRbnNCVkeHUh?=
NB6 NXHqSWkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTJ5MD6xJO69VQ>? Mn;1V2FPT0WU
COLO-680N MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrJTFdzUUN3ME2yO|IvPTJ5IN88US=> NFzLNHhUSU6JRWK=
RERF-LC-MS NUfPb2tuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnlTWM2OD1{N{[uNFA4KM7:TR?= NWfMUIt[W0GQR1XS
TGBC11TKB NE\kd4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTJ5OD6xO|gh|ryP NVXMeWRRW0GQR1XS
C8166 NXLnXop{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPTOXRKSzVyPUK3PE42ODZizszN MnLuV2FPT0WU
HDLM-2 NILITHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnsfHNXUUN3ME2yPVQvPDB7IN88US=> NGHGZXhUSU6JRWK=
IGR-1 MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LtTmlEPTB;Mkm1MlY2QSEQvF2= M37JN3NCVkeHUh?=
FADU NGLT[VhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTJ7Nz61NUDPxE1? M1TE[XNCVkeHUh?=
L-428 M3rZbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PrfWlEPTB;Mkm3MlYyPiEQvF2= MX3TRW5ITVJ?
LU-65 M2rX[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4m0c2lEPTB;M{C0MlMzKM7:TR?= MXnTRW5ITVJ?
HEL M{XsPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTNTWM2OD1|MEmuPVg{KM7:TR?= Mo\PV2FPT0WU
NCI-H810 NEn0WXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\RVmVKSzVyPUOxNE42PyEQvF2= M{\5c3NCVkeHUh?=
C3A NHLFcoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWToOmZZUUN3ME2zNVEvQDB{IN88US=> NHG4cGVUSU6JRWK=
NCI-H630 Mk\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXsTWM2OD1|M{KuNlk1KM7:TR?= MV3TRW5ITVJ?
KP-N-YN M4TQOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXWTWM2OD1|NEGuNVI{KM7:TR?= NIXvTlBUSU6JRWK=
MOLT-13 NXK1bItXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYe3[nFSUUN3ME2zOFIvOzJ4IN88US=> NF7LNJBUSU6JRWK=
NCI-H1993 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjYdnZKSzVyPUO0Nk4{PjVizszN NHTkV5FUSU6JRWK=
BE-13 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLPTWM2OD1|NESuNVY4KM7:TR?= NEDwdoRUSU6JRWK=
IST-SL1 NGPaXlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Puc2lEPTB;M{S3MlQxOSEQvF2= NUL5PGx4W0GQR1XS
TE-9 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoT2TWM2OD1|NkOuOVg6KM7:TR?= NYnISoRtW0GQR1XS
LU-135 MkTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTN4Nz6wN|Uh|ryP NVO2WXp6W0GQR1XS
T84 NVL2dWN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4SwcmlEPTB;M{e0MlcyOiEQvF2= NXjJXIZwW0GQR1XS
K-562 MkjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmriTWM2OD1|OEOuN|Yh|ryP MV3TRW5ITVJ?
SBC-5 NY\zb2sxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rLZWlEPTB;M{i2Mlk5PSEQvF2= NWe4ZZM{W0GQR1XS
NB17 NULSWI52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHjb5BKSzVyPUO5Nk42QTZizszN MX7TRW5ITVJ?
NCI-H2052 NHfnTmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\RTWM2OD1|OUiuOFczKM7:TR?= M2DBN3NCVkeHUh?=
HCC38 NH;Re49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DyWGlEPTB;NECxMlU6OyEQvF2= MnTVV2FPT0WU
NCI-H69 M3LSUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoS1TWM2OD12NEGuNFg{KM7:TR?= M{W0V3NCVkeHUh?=

... Click to View More Cell Line Experimental Data
In vivo MK-2206 shows 60% TGI and inhibits more than 70 % of phospho-Akt1/2 (T308 and S473) in A2780 ovarian cancer xenografts at a dose of 240 mg/kg. [1] MK-2206 exhibits significant antitumor activity in NCI-H292 xenograft in combination with erlotinib or lapatinib. [2]

Protocol

Kinase Assay:

[4]
+ Expand

Akt kinases assay:

Akt kinases are assayed by a GSK-derived biotinylated peptide substrate. The extent of peptide phosphorylation is determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide. When the Lance and APC are in proximity, a non-radiative energy transfer takes place from the Lance to the APC, followed by emission of light from APC at 655 nm. Working Solution: 100X protease inhibitor cocktail (PIC): 1mg/mL benzamidine, 0.5 mg/mL pepstatin, 0.5 mg/mL leupeptin, 0.5 mg/mL aprotinin; 10X assay buffer: 500 mM HEPES, pH7.5, 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-glycerol phosphate; Quench buffer 50 mM HEPES pH 7.3, 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM labeled monoclonal antibody, 0.0067 mg/mL SA-APC; ATP/MgCl2 working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, active Akt; Peptide working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, 2 TM GSK biotinylated peptide. The reaction is assembled by adding 16 µL of ATP/MgCl2 working solution to the appropriate wells. MK-2206 or vehicle (1.0 µL) is added followed by 10 µL of peptide working solution. The reaction is started by adding 13 μL of the enzyme working solution and mixing. The reaction is allowed to proceed for 50 min and then stopped by the addition of 60 µL HTRF quench buffer. The stopped reactions are incubated at room temperature for at least 30 min and then read in the instrument.
Cell Research:

[2]
+ Expand
  • Cell lines: A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6 and NCI-H460 cells
  • Concentrations: 0, 0.3, 1 and 3 μM
  • Incubation Time: 72 or 96 hours
  • Method:

    MK-2206 is dissolved in DMSO as a stock solution and diluted by culture media before use. Cells are seeded at a density of 2-3 × 103 in 96-well plates and incubated for 24 hours. Then MK-2206 (0, 0.3, 1 and 3 μM) is added to the cells. Cell proliferation is determined after 72 or 96 hours.


    (Only for Reference)
Animal Research:

[2]
+ Expand
  • Animal Models: SK-OV-3, NCI-H292, HCC70, PC-3, and NCI-H460 models in male CD1-nude mice
  • Formulation: Formulated in 30% Captisol
  • Dosages: 120 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL (29.14 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
15% Captisol
For best results, use promptly after mixing. 		17 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 480.39
Formula

C25H21N5O.2HCl
CAS No. 1032350-13-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01306045 Recruiting Carcinoma, Non-Small-Cell Lung|Carcinoma, Small Cell Lung|Carcinoma, Thymic National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 21, 2011 Phase 2
NCT01802320 Active, not recruiting Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer National Cancer Institute (NCI) March 2013 Phase 2
NCT01783171 Active, not recruiting Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unresectable Pancreatic Carcinoma National Cancer Institute (NCI) January 2013 Phase 1
NCT01776008 Active, not recruiting Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01859182 Withdrawn Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Localized Unresectable Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage II Gallbladder Cancer|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01705340 Terminated Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer National Cancer Institute (NCI) September 2012 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is your recommendation for preparing the solution and how would you deliver it to the mice (i.p. or gavage)?

  • Answer:

    You can resuspend MK-2206 in 15% Captisol at up to 17mg/ml. It's a suspension and is for oral gavage use only.

  • Question 2:

    I would want to know if MK-2206 could cross the blood brain barrier?

  • Answer:

    MK-2206 can cross BBB based on the following reference: https://clinicaltrials.gov/ct2/show/NCT01249105.

selleck catalog

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

  • Selective Akt Inhibitor

    CCT128930 AKT2-selective, IC50=6 nM.

  • Most Potent Akt Inhibitor

    AZD5363 Akt1, IC50=3 nM; Akt2, IC50=8 nM; Akt3, IC50=8 nM.

  • Akt Inhibitor in Clinical Trial

    Perifosine (KRX-0401) Phase III fro relapsed and refractory multiple myeloma.

  • Newest Akt Inhibitor

    AZD5363 Potent inhibitor of all isoforms of Akt (Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM, similar to P70S6K/PKA and lower activity towards ROCK1/2.

Related Akt Products

  • Afuresertib (GSK2110183) New

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • AT13148 New

    AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.

  • SC79 New

    SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.

  • AZD5363

    AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

    Features:Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.

  • Ipatasertib (GDC-0068)

    Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.

  • GSK690693

    GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. Phase 1.

  • Perifosine (KRX-0401)

    Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

  • A-674563

    A-674563 is an Akt1 inhibitor with Ki of 11 nM in cell-free assays, modest potent to PKA and >30-fold selective for Akt1 over PKC.

    Features:Orally bioavailable compound (achieved by replacing indole of A-443654 with phenyl moiety) and somewhat less selective for Akt over PKA than A-443654.

  • Triciribine

    Triciribine is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.

  • Honokiol

    Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Phase 3.

Tags: buy MK-2206 2HCl | MK-2206 2HCl supplier | purchase MK-2206 2HCl | MK-2206 2HCl cost | MK-2206 2HCl manufacturer | order MK-2206 2HCl | MK-2206 2HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID